|
|
Substance Name: Ribociclib [USAN:INN]
RN: 1211441-98-3
UNII: TK8ERE8P56
InChIKey: RHXHGRAEPCAFML-UHFFFAOYSA-N
Notes
- Inhibits both CDK4 and CDK6.
- NCI: An orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. (NCI Thesaurus)
Molecular Formula
- C23-H30-N8-O
Molecular Weight
- 434.545
Classification Codes
- Antineoplastic
- Antineoplastic Agents
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Ribociclib [USAN:INN]
Synonyms
- Kisqali
- LEE 011
- LEE-011
- LEE011
- LEE011A
- Ribociclib
- UNII-TK8ERE8P56
Registry Numbers
CAS Registry Number
- 1211441-98-3
FDA UNII
- TK8ERE8P56
System Generated Number
- 1211441983